Study guide

1.3 The Initial Prenatal Laboratory Panel

AMCB Certified Nurse-Midwife CNM

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care

1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral

2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts

2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy

3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy

3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy

4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss

4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care

5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance

5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion

6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation

6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy

7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair

7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture

8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation

8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications

9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage

9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation

10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health

10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis

11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination

11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes

12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days

12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days

13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization

13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening

14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation

14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral

15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders

15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome

16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause

16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis

17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions

17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking

18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity

18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care

1.3 The Initial Prenatal Laboratory Panel

Key Takeaways Explain This Topic AI

Unsensitized Rh-negative patients receive 300 mcg RhD immune globulin routinely at 28 weeks and within 72 hours of birth of an Rh-positive newborn or any potential fetomaternal hemorrhage event.

Anemia in pregnancy is defined as hemoglobin below 11.0 g/dL in the first and third trimesters and below 10.5 g/dL in the second trimester.

Benzathine penicillin G is the only therapy proven to treat fetal syphilis, so a patient with documented penicillin allergy must undergo formal desensitization rather than receive an alternative antibiotic.

An infant born to an HBsAg-positive patient must receive both hepatitis B immune globulin and single-antigen hepatitis B vaccine in separate limbs within 12 hours of birth.

Asymptomatic bacteriuria of 100,000 CFU/mL or more progresses to pyelonephritis in up to 30 to 40 percent of untreated pregnancies and requires a test-of-cure culture 1 to 2 weeks after therapy.

Last updated: September 2026

Initial Routine Prenatal Laboratory Panel

Every pregnant patient should be offered a comprehensive laboratory assessment at the initial visit. The CNM must understand the rationale, normal ranges, and clinical interventions for each test.

  • Comprehensive Initial Panel Review Initial Prenatal Panel
  • ├── Hematology & Blood Bank
  • │ ├── ABO & Rh(D) Type (RhoGAM protocol if Rh-negative)
  • │ ├── Indirect Coombs (Antibody screen for irregular erythrocyte antibodies)
  • │ └── CBC with Differential (Hgb <11.0 g/dL = 1st/3rd trimester anemia; MCV <80 fL triggers electrophoresis)
  • ├── Infectious Disease Screening
  • │ ├── Rubella IgG (MMR is live virus; non-immune get postpartum vaccine)
  • │ ├── Varicella IgG (Non-immune exposed get VZIG within 96h to 10 days)
  • │ ├── Syphilis: RPR/VDRL or Reverse Algorithm (Benzathine penicillin G is only curative therapy)
  • │ ├── Hepatitis B: HBsAg (If positive: infant needs HBIG + HepB vaccine within 12h; check HBV DNA)
  • │ └── HIV 4th Gen Ag/Ab Screen (Universal opt-out; viral load suppression prevents transmission)
  • └── Renal & Genitourinary
  • ├── Urine Culture & Susceptibility (Screens for asymptomatic bacteriuria ≥10^5 CFU/mL)
  • └── Cervical Cytology & STI NAAT (Chlamydia/Gonorrhea NAAT universal for age <25 or high risk)
  • Detailed Laboratory Rationale & Midwifery Interventions

ABO & Rh(D) Typing & Antibody Screen:

Rh-Negative Patients: Unsensitized Rh-negative women receive 300 mcg RhD immune globulin (RhoGAM) routinely at 28 weeks gestation and within 72 hours postpartum if the neonate is Rh-positive. RhIG is also indicated within 72 hours of any potential fetomaternal hemorrhage (miscarriage, ectopic, CVS, amniocentesis, abdominal trauma, external cephalic version, or antepartum bleeding).

Atypical Antibodies: Anti-D is the most common cause of hemolytic disease of the fetus and newborn (HDFN). However, anti-Kell (K) antibodies are particularly virulent; anti-Kell causes severe fetal anemia not merely through hemolysis, but by destroying erythroid progenitor cells in fetal liver. Any titer of anti-Kell requires maternal-fetal medicine (MFM) consultation and middle cerebral artery (MCA) Doppler surveillance.

Complete Blood Count (CBC):

Physiologic Anemia of Pregnancy: Plasma volume expands by 45–50%, whereas red cell mass expands by 20–30%, leading to physiologic hemodilution.

Diagnostic Cutoffs for Anemia:

  • First trimester: Hemoglobin <11.0 g/dL (Hematocrit <33%)
  • Second trimester: Hemoglobin <10.5 g/dL (Hematocrit <32%)
  • Third trimester: Hemoglobin <11.0 g/dL (Hematocrit <33%)

Microcytic Anemia (MCV <80 fL): Triggers serum ferritin to assess iron stores and hemoglobin electrophoresis to evaluate for beta-thalassemia minor, sickle cell trait, or other hemoglobinopathies.

Rubella and Varicella Immunity:

Assessed via quantitative or qualitative IgG titers.

Rubella Non-Immune: Congenital rubella syndrome causes cataracts, sensorineural deafness, and cardiac defects (PDA). The MMR vaccine is a live attenuated virus and is strictly contraindicated during pregnancy . The patient must be counseled to avoid known exposures and receive the MMR vaccine immediately postpartum prior to hospital discharge .

Varicella Non-Immune: If a non-immune pregnant woman has close contact with an individual with chickenpox or shingles, administer Varicella-Zoster Immune Globulin (VariZIG) within 96 hours (acceptable up to 10 days) to prevent severe maternal complications like varicella pneumonia.

Syphilis Serology:

Universal screening at initial visit; repeated in early third trimester (28 weeks) and at delivery for high-risk populations.

Algorithms: Traditional (nontreponemal RPR/VDRL confirmed by treponemal FTA-ABS or TP-PA) vs. Reverse sequence (automated treponemal immunoassay confirmed by quantitative RPR). Discrepant results require a secondary treponemal assay (TP-PA).

Treatment: Benzathine penicillin G (2.4 million units IM) is the only proven curative therapy that crosses the placenta to treat the fetus. Patients with a documented severe penicillin allergy must undergo formal penicillin desensitization followed by penicillin therapy; erythromycin, azithromycin, and doxycycline are unacceptable in pregnancy.

Jarisch-Herxheimer Reaction: Acute febrile reaction with uterine contractions and transient fetal heart rate decelerations within 24 hours of starting penicillin in early syphilis; patients require anticipatory guidance.

Hepatitis B Surface Antigen (HBsAg):

Positive HBsAg indicates acute or chronic maternal infection.

Neonatal Management: Within 12 hours of birth , the infant must receive both Hepatitis B Immune Globulin (HBIG) and the single-antigen Hepatitis B vaccine in separate anatomical limbs.

Maternal Management: Check maternal HBV DNA viral load in second trimester; if HBV DNA >200,000 IU/mL, initiate maternal antiviral therapy (tenofovir disoproxil fumarate) at 28–32 weeks to decrease perinatal transmission.

Urine Culture for Asymptomatic Bacteriuria (ASB):

Defined as isolation of ≥10^5 Colony-Forming Units (CFU)/mL of a single bacterial pathogen in a clean-catch midstream urine sample from an individual without urinary symptoms.

Pathophysiology: High progesterone levels induce smooth muscle relaxation, ureteral dilatation, and reduced bladder tone, while the enlarging dextrorotated uterus compresses the ureters at the pelvic brim. Untreated ASB progresses to acute pyelonephritis in up to 30–40% of affected pregnancies, carrying substantial risks of septic shock, acute respiratory distress syndrome (ARDS), and preterm labor.

Treatment: Prescribe a 5- to 7-day oral regimen based on susceptibility (e.g., nitrofurantoin, cephalexin, or amoxicillin-clavulanate). A test-of-cure urine culture is mandatory 1 to 2 weeks post-treatment .